Search details
1.
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
Blood
; 120(8): 1570-80; quiz 1752, 2012 Aug 23.
Article
in English
| MEDLINE | ID: mdl-22715121
2.
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
Clin Cancer Res
; 14(9): 2717-25, 2008 May 01.
Article
in English
| MEDLINE | ID: mdl-18451237
3.
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Lancet Haematol
; 2(9): e357-66, 2015 Sep.
Article
in English
| MEDLINE | ID: mdl-26685769
4.
Sensitive monitoring of acute promyelocytic leukemia by PML-RARA DNA Q-PCR.
Leuk Lymphoma
; 58(7): 1767-1769, 2017 07.
Article
in English
| MEDLINE | ID: mdl-27899039
5.
Atypical presentation of therapy-related acute promyelocytic leukaemia with marrow fibrosis.
Pathology
; 48(3): 286-8, 2016 Apr.
Article
in English
| MEDLINE | ID: mdl-27020510
Results
1 -
5
de 5
1
Next >
>>